Illumina, Inc. (NASDAQ:ILMN) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Illumina, Inc.

Illumina said adding SomaLogic would support the company’s multiomics strategy and strengthen the value of its NovaSeq X ...

Illumina, Inc. (NASDAQ: ILMN) today announced a new spatial technology program that will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale.

In recent years, Novogene Europe has systematically integrated state-of-the-art technologies across its service portfolio, ...

For reference, after the Human Genome Project took 13 years and $2.7 billion to complete in 2003, Illumina’s technology helped reduce the cost of whole genome sequencing faster than Moore’s ...

Illumina stock slid on Tuesday after China banned imports of the biotech’s gene sequencing machines as part of a broader retaliatory response to U.S. tariffs. Shares of Illumina slipped 3.6% to ...

Less than two years after Boulder-based biotech firm SomaLogic Inc. merged with Standard BioTools Inc. (Nasdaq: LAB), ...

Illumina, Inc. will acquire SomaLogic for $350 million plus performance-based milestones. The acquisition advances Illumina's multiomics strategy, combining SomaLogic's proteomics technology with ...

Furthermore, Illumina sequencing generally offers higher accuracy (around 99%) compared to nanopore sequencing, which typically ranges from 92% to 97%. Choosing Between Illumina and Nanopore ...

The Rise of a Frenzied Trading Style Cathie Wood, founder of ARK Invest, burst into investor consciousness in 2020 when her ...

Illumina inked a deal with Standard BioTools to acquire SomaLogic for $350 million in cash. The maker of gene-sequencing equipment and services said Monday that the deal includes an additional payout ...

Leveraging Illumina's advanced spatial technology, which provides an expansive 50 mm by 15 mm imaging area for enhanced flexibility, sensitivity, resolution, and unbiased whole-transcriptome ...